INNOVA CAPTAB LIMITED

BSE: INNOVACAP544067ISIN INE0DUT01020

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹1,034.75+31.55 (+3.14%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,350.05
52W low: ₹608.25
Off 52W high: -23.35%
1M return: -9.64%
3M return: +9.66%
6M return: +18.19%
1Y return: +25.28%
20D avg volume: 3,673
50 DMA: ₹1,110.25
200 DMA: ₹893.70

Key ratios Consolidated

Market cap: ₹5,921 Cr
Current price: ₹1,034.75
52W high / low: ₹1,350.05 / ₹608.25
Face value: ₹10.00
P/E: 37.89
P/B: 5.43
EPS (TTM): ₹27.31
Book value / share: ₹190.61
ROE: —
ROCE: 15.30%
Operating margin: —
Net margin: —
Debt / equity: 0.32
Net debt: ₹340.49 Cr
Interest cover: 12.14
Dividend yield: 0.19%
Dividend / share (TTM): ₹2.00
Payout: 7.32%
Cash conversion cycle: 90.0 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	470.85	447.80	450.29	380.38	351.54	314.74	316.46	318.20	294.27	262.63	302.49	282.94
	2.01	1.56	1.65	4.19	4.48	3.38	4.33	2.22	2.12	5.68	2.34	3.34
	472.86	449.37	451.95	384.57	356.02	318.12	320.79	320.42	296.39	268.32	304.82	286.28
	413.87	398.69	396.27	345.34	313.35	278.81	275.20	273.61	257.09	228.77	269.62	256.10
	307.98	261.24	280.84	233.94	229.44	210.93	195.76	205.02	188.12	160.05	190.94	178.73
	12.39	32.58	15.06	5.65	5.05	5.29	11.18	14.27	8.47	12.02	6.00	9.38
	44.79	42.62	43.78	41.72	39.09	35.52	28.21	28.17	24.88	25.90	25.63	24.25
	4.43	4.59	3.95	5.50	2.86	1.95	0.17	0.15	0.14	0.81	6.80	8.81
	11.71	11.39	11.42	11.32	11.04	9.80	5.13	4.99	4.85	3.41	4.93	4.83
	49.06	43.44	45.30	43.22	39.62	33.52	31.76	—	—	30.39	—	—
	58.98	50.67	55.68	39.23	42.68	39.31	45.59	46.81	39.31	39.55	35.20	30.18
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	58.98	50.67	55.68	39.23	42.68	39.31	45.59	46.81	39.31	39.55	35.20	30.18
	14.86	12.59	13.53	9.56	11.66	9.74	11.38	11.80	9.83	10.82	10.07	7.28
	44.13	40.35	42.15	29.67	31.02	29.57	34.20	35.00	29.48	28.72	25.13	22.91
	7.71	7.05	7.37	5.18	5.42	5.17	5.97	6.12	5.15	5.02	4.39	4.77
Key metrics
	75.12	66.65	71.05	56.05	56.58	51.06	50.89	51.95	44.30	43.77	46.93	43.82
	16.00%	14.90%	15.80%	14.70%	16.10%	16.20%	16.10%	16.30%	15.10%	16.70%	15.50%	15.50%
	9.40%	9.00%	9.40%	7.80%	8.80%	9.40%	10.80%	11.00%	10.00%	10.90%	8.30%	8.10%
	—	4.10%	—	3.50%	—	3.40%	—	—	—	—	—	—
	33.90%	42.30%	42.30%	19.50%	19.50%	19.80%	4.60%	12.50%	—	—	—	—
	42.30%	36.50%	23.20%	-15.20%	5.20%	3.00%	36.10%	52.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,749	1,630	1,244	1,081
	9.41	7.42	12.04	12.49
	1,759	1,637	1,256	1,094
	1,554	1,449	1,085	964.26
	1,084	1,005	799.82	696.12
	65.68	58.33	39.22	35.54
	172.91	167.20	116.78	90.66
	18.47	16.90	2.40	21.46
	45.84	45.18	24.78	15.96
	181.02	167.10	126.65	107.85
	204.56	188.26	171.02	129.53
	0.00	0.00	0.00	0.00
	204.56	188.26	171.02	129.53
	50.54	47.35	42.76	35.18
	156.30	143.18	128.26	94.34
	27.31	25.02	22.41	18.66
Key metrics
	268.87	250.34	198.20	166.95
	15.37%	15.40%	15.90%	15.40%
	8.93%	8.80%	10.30%	8.70%
	—	15.30%	14.10%	—
	34.47%	31.10%	15.00%	—
	20.43%	11.60%	36.00%	—
	—	48.17	-108.66	—
	—	0.81	0.50	—
	—	0.32	0.35	—
	—	340.49	322.59	—
	—	90.0	99.1	—
Balance sheet
	—	1,837	1,580	—
	—	922.96	695.69	—
	—	3.20	15.52	—
	—	437.29	331.64	—
	—	283.26	208.00	—
	—	69.90	55.10	—
	—	823.33	812.43	—
	—	318.63	201.80	—
	—	494.58	353.00	—
	—	343.69	338.11	—
	—	127.87	93.22	—
	—	215.82	244.89	—
	—	1,091	959.42	—
Cash flow
	—	116.52	63.84	—
	—	-107.12	-151.59	—
	—	-21.71	91.53	—
	—	68.35	172.50	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	400.48	358.28	363.73	289.83	286.98	242.52	248.53	240.18	226.83	198.10	236.46	211.73
	2.70	2.68	3.21	4.63	4.32	4.36	3.49	4.28	4.64	6.01	1.77	2.11
	403.18	360.96	366.93	294.46	291.29	246.88	252.02	244.46	231.47	204.11	238.23	213.84
	360.14	333.02	329.61	275.19	264.00	224.02	219.25	210.15	201.53	177.76	212.72	193.46
	280.37	236.32	256.49	205.10	203.46	187.42	175.12	183.10	169.87	145.10	171.47	157.49
	6.50	27.51	8.64	0.41	1.28	0.23	0.13	0.18	0.14	4.98	0.15	1.25
	30.34	28.20	30.05	27.50	25.34	21.32	14.75	14.72	11.96	13.11	13.30	12.13
	4.03	3.98	3.47	5.21	2.77	1.87	0.13	0.08	0.09	0.12	3.81	5.20
	9.68	9.40	9.41	9.48	9.08	7.81	3.08	3.07	3.06	2.93	2.97	2.81
	29.97	27.32	26.14	24.40	23.15	18.98	—	—	—	16.44	15.73	13.21
	43.03	27.93	37.33	19.27	27.29	22.86	32.77	34.32	29.95	26.35	25.51	20.38
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	43.03	27.93	37.33	19.27	27.29	22.86	32.77	34.32	29.95	26.35	25.51	20.38
	10.97	6.77	9.43	4.93	7.00	5.73	8.37	8.71	7.61	6.63	6.86	5.91
	32.06	21.16	27.90	14.33	20.30	17.12	24.40	25.61	22.34	19.72	18.65	14.47
	5.60	3.91	4.88	2.50	3.55	2.99	4.26	4.48	3.90	3.45	3.26	3.02
Key metrics
	56.74	41.31	50.21	33.96	39.14	32.54	35.98	37.47	33.10	29.40	32.29	28.39
	14.20%	11.50%	13.80%	11.70%	13.60%	13.40%	14.50%	15.60%	14.60%	14.80%	13.70%	13.40%
	8.00%	5.90%	7.70%	4.90%	7.10%	7.10%	9.80%	10.70%	9.80%	10.00%	7.90%	6.80%
	—	2.80%	—	2.20%	—	2.30%	—	—	—	—	—	—
	39.50%	47.70%	46.40%	20.70%	26.50%	22.40%	5.10%	13.40%	—	—	—	—
	57.90%	23.60%	14.30%	-44.00%	-9.10%	-13.20%	30.80%	77.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,412	1,299	958.06	864.93
	13.22	13.24	16.77	10.72
	1,426	1,312	974.84	875.65
	1,298	1,200	854.95	781.95
	978.28	901.37	715.51	640.47
	43.06	37.84	0.68	6.40
	116.09	111.09	62.74	50.11
	16.69	15.42	2.17	13.59
	37.97	37.37	17.02	11.40
	107.83	99.42	68.17	61.33
	127.56	111.82	119.89	93.70
	0.00	0.00	0.00	—
	127.56	111.82	119.89	93.70
	32.10	28.13	30.42	25.54
	95.45	83.69	89.47	68.16
	16.89	14.84	15.63	13.48
Key metrics
	182.22	164.61	139.08	118.69
	12.90%	12.70%	14.50%	13.70%
	6.76%	6.40%	9.30%	7.90%
	—	11.20%	11.40%	—
	38.71%	35.60%	10.80%	—
	9.17%	-6.50%	31.30%	—
	—	-27.68	-141.13	—
	—	0.41	0.22	—
	—	0.36	0.40	—
	—	319.93	313.86	—
	—	69.3	81.0	—
Balance sheet
	—	1,547	1,365	—
	—	749.83	529.11	—
	—	1.36	15.31	—
	—	330.19	248.90	—
	—	204.21	139.94	—
	—	55.36	40.35	—
	—	646.78	636.91	—
	—	287.75	176.15	—
	—	414.25	290.16	—
	—	321.29	329.17	—
	—	105.47	84.28	—
	—	215.82	244.89	—
	—	886.65	812.97	—
Cash flow
	—	34.11	19.80	—
	—	-14.06	-99.75	—
	—	-33.99	83.86	—
	—	61.79	160.93	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +38.71%
Profit YoY (TTM): +9.17%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +34.47%
Profit YoY (TTM): +20.43%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 50.90%

Holder	Type	Holding	Previous	Change
MANOJ LOHARIWALA	Promoter	29.07%	—	—
VINAY KUMAR LOHARIWALA	Promoter	21.81%	—	—
GIAN PARKASH AGGARWAL	Public	10.19%	—	—
ARCHIT AGGARWAL	Public	8.74%	—	—
CLARUS CAPITAL I	Public	3.58%	—	—
CANARA ROBECO MUTUAL FUND	Public	3.47%	—	—
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND	Public	3.47%	—	—
360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 9	Public	2.05%	—	—
360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 10	Public	1.82%	—	—
VEENA DEVI	Public	1.75%	—	—
SBI LIFE INSURANCE CO. LTD	Public	1.29%	—	—
INVESCO INDIA SMALL CAP FUND	Public	1.24%	—	—
CHHAVI LOHARIWALA	Promoter Group	0.01%	—	—
VANDANA LOHARIWALA	Promoter Group	0.01%	—	—
Dhruv Lohariwala	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
INNOVA CAPTAB LIMITED	5,921	1,034.75	37.89	15.30%	+34.47% TTM	+20.43% TTM	+25.28%

Filings & corporate actions

Recent announcements

Pursuant to regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, we are enclosing herewith a copy of the certificate dated 07th ....7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gian Parkash Aggarwal & PACs5 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
We wish to inform you that 22nd Annual General Meeting ("AGM") of the Company was held on Wednesday, 30th September, 2026 at 11.00 A.M. through Video Conferencing ("VC") / Other Audio Visual ....2 Oct 2026 · AGM/EGM / AGM
Pursuant to the provisions of regulation 30 read with part A of schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), please ....30 Sep 2026 · AGM/EGM / AGM
Pursuant to regulation 30 read with part A of schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that ....29 Sep 2026 · Company Update / Credit Rating
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, we wish to inform you that in terms of Company''s Code of Internal Procedures ....28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to the regulation 30 read with schedule III (Part A) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like ....15 Sep 2026 · Company Update / Analyst / Investor Meet
Pursuant to the regulation 30 read with schedule III, Part A, Para A and regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing regulations") ....5 Sep 2026 · Company Update / Newspaper Publication
Pursuant to regulation 36(1)(b) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), the Company has sent physical letter to those shareholders ....5 Sep 2026 · Company Update / General
Submission of BRSR for financial year 2025-26.4 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice convening the 22nd Annual General Meeting ('AGM') and submission of Integrated Annual Report of the Company for the financial year 2025-2026.4 Sep 2026 · Others / Reg. 34 (1) Annual Report
The 22nd AGM of the Members of the Company will be held on Wednesday, 30th September, 2026 at 11.00 A.M. (IST) through Video Conferencing/Other Audio Visual Means ("VC"/"OAVM"), in accordance ....4 Sep 2026 · AGM/EGM / AGM
Pursuant to regulation 30 read with schedule iii Part A, and regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended and in compliance with general ....3 Sep 2026 · Company Update / Newspaper Publication
Pursuant to regulation 30 (read with Part A of schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), ....3 Sep 2026 · Others / Outcome without intimation
This is to inform you that the Board of Directors of the Company at its meeting commenced on 21st August 2026 at 23:16 hours (IST) and concluded on 22nd August 2026 at 00:25 hours (IST) ....23 Aug 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 and other applicable provision Board of Directors approved the AGM Notice. AGM Notice and annual report will be shared in due course.22 Aug 2026 · Company Update / General
In terms of Regulations 30 of the Listing Regulations the Board of Directors of the Company had approved a brownfield expansion of the existing manufacturing facility at 81-BEPIP Phase-1 ....22 Aug 2026 · Company Update / General
Pursuant to regulation 30(read with Part A of Schedule III) and other applicable provisions of the SEBI LODR 2015 Board of Directors at its meeting commenced on 21st August 2026 has approved ....22 Aug 2026 · Result / Financial Results
Pursuant to regulation 30 (read with Part A of schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we ....22 Aug 2026 · Board Meeting / Outcome of Board Meeting
Innova Captab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/08/2026 ,inter alia, to consider and approve Pursuant to regulation 29 of ....18 Aug 2026 · Board Meeting / Board Meeting
This is in continuation to our letter dated 12th August, 2026, where we have informed regarding the audio link of the earnings call with analysts/investors for the quarter ended 30th June, ....14 Aug 2026 · Company Update / Earnings Call Transcript
Pursuant to the provisions of Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we wish to inform you that in terms of ....13 Aug 2026 · Insider Trading / SAST / Closure of Trading Window
This is further to our intimation letter dated 07th August, 2026, and pursuant to regulation 30 read with part A of schedule lll of the Securities Exchange Board of India (Listing Obligations ....12 Aug 2026 · Company Update / Analyst / Investor Meet
This is to inform you that the Board of Directors of the Company at its meeting held on Tuesday, 11th August, 2026, has approved the unaudited (standalone and consolidated) financial results ....12 Aug 2026 · Company Update / Newspaper Publication
Pursuant to regulation 30 (read with part A of schedule lll) and other applicable provisions of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....11 Aug 2026 · Result / Financial Results
Intimation of Investor presentation for the analyst/institutional investor meeting to be held for financial result of quarter ended 30th June 2026.11 Aug 2026 · Company Update / Investor Presentation
Pursuant to regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we are enclosing herewith ....11 Aug 2026 · Company Update / Press Release / Media Release
Pursuant to regulation 30 (read with part A of schedule III) and other applicable provisions of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to regulation 29 of the Securities Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, we hereby inform you that the meeting of the Board ....6 Aug 2026 · Company Update / General
Innova Captab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of ....6 Aug 2026 · Board Meeting / Board Meeting
Pursuant to Regulation 74(5) of Securities Exchange Board of India (Depositories and Participants) Regulations, 2018 we are enclosing herewith copy of certificate dated 02nd July, 2026 ....3 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to the regulation 30 read with schedule III, Part A, Para A of SEBI LODR Regulations, 2015, as amended, we are enclosing herewith copies of the newspaper advertisements dated 25th ....25 Jun 2026 · Company Update / Newspaper Publication
Pursuant to the Provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, we wish to inform you that in terms of Company''s Code internal procedures ....25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our earlier intimation letter dated 04th June, ....24 Jun 2026 · AGM/EGM / AGM
Pursuant to regulation 30 read with schedule III Part A Para A and Regulation 47 of SEBI (LODR) 2015 as amended time to time and as per SS 2 issued by ICSI we are enclosing herewith copy ....6 Jun 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 36(1)(b) of SEBI(LODR)2015 the Company is sending physical to those shareholders whose email address is not registered with Company/Depository Participant/ Depositories ....5 Jun 2026 · Company Update / General
Pursuant to Regulation 34(2)(f) of SEBI (LODR) 2015 please find enclosed Business Responsibility and Sustainability Report (BRSR) for FY 2025-26.4 Jun 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
The 22nd Annual General Meeting ('AGM') of the Members of Innova Captab Limited will be held on Monday, 29th June, 2026 at 11:00 A.M. (IST) through Video Conferencing/Other Audio Visual ....4 Jun 2026 · Others / Reg. 34 (1) Annual Report
The 22nd Annual General Meeting (AGM) of Members of Innova Captab Limited will be held on Monday 29th June 2026 at 11:00 AM (IST) through Video Conferencing / other Audio Visual Means ("VC"/"OVAM") ....4 Jun 2026 · AGM/EGM / AGM
Pursuant to the Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended and in compliance with applicable General circular ....3 Jun 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 2.0000	30 Jan 2026	30 Jan 2026	—

Board meetings

21 Aug 2026 Board Meeting - Financial Results
11 Aug 2026 Board Meeting - Financial Results